Specialty firm adding reps for hot-flash gel

Share this article:
Bradley Pharmaceuticals is hiring about 60 reps as it gears up to launch Elestrin, a low-dose estrogen gel for treating the symptoms of menopause.

The reps will pitch Elestrin to OB/GYNs as part of Bradley’s Kenwood Therapeutics division, which received FDA approval for the product last December.

The company estimates the size of the US estrogen therapy market, which consists of oral and topical products, at $1.3 billion. The topical market is only worth about $300 million.

Bradley in-licensed Elestrin from BioSante Pharmaceuticals late last year and has the exclusive US marketing rights.

The small specialty firm says Elestrin fits into its strategic plan to in-license Phase II and Phase III drugs with long- term intellectual property protection and bring them to market. Elestrin’s patent protects it until 2022.

Share this article:

Email Newsletters

More in News

Astellas, DOJ settle for $7.3M

Astellas, DOJ settle for $7.3M

Astellas has settled a False Claims case with the Department of Justice over the 2010-2013 marketing of an antifungal medication. Astellas denies the allegations.

Boehringer drug lands US, EU orphan tag

Boehringer drug lands US, EU orphan tag

The experimental Breakthrough Therapy treatment is for acute myeloid leukemia.

Omnio app moves to smartphones

Omnio app moves to smartphones

Physicians Interactive is introducing the third wave of its Omnio app, making the tablet-only tool available for iPhones and Android phones.